Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey

• Ngā kaituhi matua: Katarzyna Bobeff (Author), Agata Pastorczak (Author), Zuzanna Urbanska (Author), Walentyna Balwierz (Author), Edyta Juraszewska (Author), Jacek Wachowiak (Author), Katarzyna Derwich (Author), Magdalena Samborska (Author), Krzysztof Kalwak (Author), Iwona Dachowska-Kalwak (Author), Paweł Laguna (Author), Iwona Malinowska (Author), Katarzyna Smalisz (Author), Jolanta Gozdzik (Author), Aleksandra Oszer (Author), Bartosz Urbanski (Author), Maciej Zdunek (Author), Tomasz Szczepanski (Author), Wojciech Mlynarski (Author), Szymon Janczar (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2023-04-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Venetoclax, the best established BH3-mimetic, is a practice-changing proapoptotic drug in blood cancers in adults. In paediatrics the data are fewer but exciting results were recently presented in relapsed or refractory leukaemias demonstrating significant clinical activity. Importantly, the in-terv...